News Scotland to fund BMS skin cancer combo Patient evidence convinces SMC Opdivo+Yervoy is cost-effective.
News BMS' Opdivo still streets ahead of Merck rival BMS to refocus operations, according to Q3 results.
News AZ halts recruitment on head and neck cancer trial FDA calls for hold after reports of bleeding.
Views & Analysis ESMO review: advances in immunotherapy, EMA dialogue and pa... QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s congress.
Partner Content Partner Content Giving drug candidates the greatest chance for success With the advent of new targeted treatments and immunotherapies, Quintiles has provided clinical services for over 700 phase 1 and phase 2 oncology studies since 2011.
Views & Analysis Immuno-oncology: how to keep ahead in a fast-moving field In the last two years, the first PD-1 checkpoint inhibitor drugs to reach patients have launched a revolution in cancer care.
News Relief for AZ as Truqap hits the spot in prostate cancer After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
